POST Online Media Lite Edition


Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors

Staff writer |
Berkeley, Ca., USA - January 27, 2008, Berkeley, Ca., USA - Nile Therapeutics, Inc., a biopharmaceutical company, announced the appointment of Gregory W. Schafer to its board of directors and as chairman of the audit committee.

Article continues below

Mr. Schafer earned an MBA from the Anderson Graduate School of Management at UCLA and a BSE in Mechanical Engineering from the University of Pennsylvania. Mr. Schafer worked as a management consultant for Deloitte & Touche LLP, and after that he served as Director of Finance of Cerus (1997-1999) and as Vice President and Chief Financial Officer of Cerus Corporation (1999-2004). From 2004 to 2006, Mr. Schafer served as a consultant to various public companies in the biotechnology industry including IntraBiotics Pharmaceuticals (January 2005-September 2005). Gregory W. Schafer has served as Onyx's Vice President and Chief Financial Officer since April 2006 and prior to that was a consultant to Onyx beginning in March 2


What to read next

Jennerex appoints Gregory W. Schafer as CFO
Nile Therapeutics appoints Arie S. Belldegrun to board of directors
Nile Therapeutics promotes Darlene Horton to CEO and director